Biochemistry

Two Day Online Seminar for Designing and Sustaining New and Existing Pharma/Biotech Product Stability Testing Program (October 6-7, 2021) - ResearchAndMarkets.com

Monday, July 26, 2021 - 1:54pm

Performing an effective sampling plan and utilizing the appropriate sample size for a stability testing program.

Key Points: 
  • Performing an effective sampling plan and utilizing the appropriate sample size for a stability testing program.
  • Performing a compliant sample analysis, handling and effecting the appropriate test specification for the product type.
  • How to Effectively Handle, Manage Data, Utilize and Perform the Trending of Stability Testing Results and Data.
  • Knowledge Base: Attendees will gain an understanding in the following key areas:
    How to perform Quality Control Testing, Setting Test Specification and Assay Release Process in a Stability Testing Program.

$5.5+ Billion Global Sequencing Reagents Market to 2028 - by Technology, Application, Reagent Type, End-user and Geography - ResearchAndMarkets.com

Friday, July 23, 2021 - 11:14am

The "Sequencing Reagents Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Technology; Application; Reagent Type; End User; Geography."

Key Points: 
  • The "Sequencing Reagents Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Technology; Application; Reagent Type; End User; Geography."
  • The global sequencing reagents market is expected to reach US$ 14,195.60 million by 2028 from US$ 5,530.32 million in 2020; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028.
  • The factors such as growing funding for genomics, declining cost of sequencing procedures, and increasing prevalence of chronic diseases drive the market growth.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Galleon Gold Extends Gold Mineralization on Eastern Flank at West Cache Project

Wednesday, July 21, 2021 - 12:45pm

Toronto, Ontario--(Newsfile Corp. - July 21, 2021) - Galleon Gold Corp. (TSXV: GGO) (the "Company" or "Galleon Gold") is pleased to announce final assay results from the 2021 East Pit extension drill program at the Company's 100% owned West Cache Gold Project, Timmins, Ontario.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 21, 2021) - Galleon Gold Corp. (TSXV: GGO) (the "Company" or "Galleon Gold") is pleased to announce final assay results from the 2021 East Pit extension drill program at the Company's 100% owned West Cache Gold Project, Timmins, Ontario.
  • With all assays now complete for this area, results continue to confirm the easterly extension of multiple gold zones.
  • This was the second set of holes targeting the eastern margins of our known mineralization, and results confirm the trend is open-ended and our pit and underground potential continues to grow.
  • Close-up photos of the East Extension mineralization with corresponding gold grades can be seen in Figure 5.

Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma

Thursday, July 15, 2021 - 12:30pm

Sigyn Therapy is a proprietary blood purification technology designed to deplete pathogens, toxins and inflammatory targets from the bloodstream of treated patients.

Key Points: 
  • Sigyn Therapy is a proprietary blood purification technology designed to deplete pathogens, toxins and inflammatory targets from the bloodstream of treated patients.
  • 32% of ammonia was eliminated from human blood plasma in one hour and an average elimination of 37% was reported at four hours.
  • We created Sigyn Therapy to overcome the limitations of previous blood purification technologies, stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics.
  • In previous studies, Sigyn Therapy demonstrated the simultaneous depletion of endotoxin, TNF-a, IL-6 and IL-1b from human blood plasma.

BERG To Present Latest Glioblastoma [GBM] Treatment Data At Society For Neuro-Onocology 2021 Meeting

Wednesday, July 14, 2021 - 2:30pm

"Brain cancers, such as GBM, are destroying patients and their families," said Dr.Niven R. Narain, CEO, President and Co-founder of BERG.

Key Points: 
  • "Brain cancers, such as GBM, are destroying patients and their families," said Dr.Niven R. Narain, CEO, President and Co-founder of BERG.
  • BPM 31510 is a unique therapeutic modality, that specifically targets cell metabolism and shifts the cancer's glycolytic dependency toward mitochondrial oxidative phosphorylation.
  • BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology, to map disease and revolutionize treatments across oncology, neurology and rare diseases.
  • We are grateful to our patient and family partners for their participation in these critical efforts to improve cancer care.

10x Genomics Introduces New Chromium X Series for Single Cell Analysis

Wednesday, July 14, 2021 - 1:00pm

PLEASANTON, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Building on its industry leading position in single cell analysis, 10x Genomics (NASDAQ: TXG) today announced commercial availability of its new Chromium X Series, a next-generation platform for single cell analysis.

Key Points: 
  • PLEASANTON, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Building on its industry leading position in single cell analysis, 10x Genomics (NASDAQ: TXG) today announced commercial availability of its new Chromium X Series, a next-generation platform for single cell analysis.
  • The Chromium X, which has been in development for more than two years, delivers extensive scale and operational simplicity for single cell analysis.
  • The new Chromium X Series is a milestone for us and our most ambitious project to date, saidBen Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics.
  • The Chromium X Series is compatible with all of the companys existing low throughput and standard single cell assays and is supported by the 10x Genomics Cloud Analysis offering for data management, analysis and collaboration.

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

Tuesday, July 13, 2021 - 1:20pm

11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • 11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).
  • The issuance of the 11054408 patent is the third patent granted to StemoniX: additional applications are currently pending worldwide.
  • Human iPSCs offer many advantages over recombinant cell lines or primary rodent cells for use in drug screening.
  • Vyant Bio, Inc. (Vyant Bio, the Company) (Nasdaq: VYNT) is emerging as an advanced biotechnology drug discovery company.

Anthony P. Morise is being recognized by Continental Who's Who

Friday, July 9, 2021 - 7:56pm

Va., July 9, 2021 /PRNewswire/ -- Anthony P. Morise is being recognized by Continental Who's Who as a Trusted Cardiologist for his exceptional work in the field of Lipidology and Cardiology and in recognition of his work at West Virginia University Heart and Vascular Institute.

Key Points: 
  • Va., July 9, 2021 /PRNewswire/ -- Anthony P. Morise is being recognized by Continental Who's Who as a Trusted Cardiologist for his exceptional work in the field of Lipidology and Cardiology and in recognition of his work at West Virginia University Heart and Vascular Institute.
  • Dr. Morise currently works for the West Virginia University Heart and Vascular Institute in Morgantown.
  • Dr. Morise is currently working on several clinical trials involving lipid disorders, and often sees and treats patients who have genetic lipid disorders.
  • Dr. Morise is board-certified in Internal Medicine and Cardiovascular Disease by the American Board of Internal Medicine (ABIM).

Spanish Mountain Gold Reports Assay Results from Resource Expansion Program: Multiple Long Intercepts in All Four Tested Areas

Tuesday, July 6, 2021 - 1:30pm

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Spanish Mountain Gold Ltd. (TSXV: SPA) (the "Company") is pleased to announce the assay results from the latest resource expansion program for the Spanish Mountain Gold Project (the "Project") located in British Columbia, Canada.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Spanish Mountain Gold Ltd. (TSXV: SPA) (the "Company") is pleased to announce the assay results from the latest resource expansion program for the Spanish Mountain Gold Project (the "Project") located in British Columbia, Canada.
  • Notably, the assay results report long intercepts (up to 68.58 m in length) in all four tested areas with grades higher than the economic cut-off established in the latest resource estimate (published along with the PFS).
  • The Company has retained Discovery Consultants of Vernon, BC, to monitor independently the quality control and quality assurance (QC/QA) data on the Spanish Mountain Gold Project.
  • Spanish Mountain Gold Ltd. is focused on advancing its 100%-owned Spanish Mountain gold project in southern central British Columbia.

Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

Tuesday, July 6, 2021 - 2:17pm

Sirnaomics' lead product candidate, STP707, is an anti-cancer siRNA (small interfering RNA) therapeutic.

Key Points: 
  • Sirnaomics' lead product candidate, STP707, is an anti-cancer siRNA (small interfering RNA) therapeutic.
  • "The IND green light from the U.S. FDA for Sirnaomics' first IV oncology drug, STP707, represents another major milestone for the company's mission in discovery and development of novel siRNA therapeutics for unmet clinical needs.
  • "Sirnaomics is currently in a strong position to lead the RNAi community in the development of novel oncology therapeutics."
  • "This IND approval represents a very important moment for the company as we can now expand our therapeutic reach in IV administration.